Skip to main content
Main navigation
Home
About pCPA
Who We Are
Governance
FAQs
Negotiations
Recent Updates
Forms and Publications
Brand Name Drugs
Negotiations Status
Negotiation Process
Generic Drugs
Biologics/Biosimilars
Contact Us
EN
FR
Faslodex (fulvestrant)
pCPA File Number:
20989
Negotiation Status:
Concluded without agreement
Indication(s):
Locally Advanced or Metastatic Breast Cancer
Sponsor/Manufacturer:
AstraZeneca Canada Inc.
CADTH Project Number:
pCODR 10110
pCPA Engagement Letter Issued:
2018-08-03
Negotiation Process Concluded:
2019-01-29